The Oxford-based AI medical imaging platform has raised the addition to its Series C funding to enable it to expand further in the US market.
Oxford-based AI medical imaging platform Brainomix has extended its Series C funding by £4.8 million. This is on top of the £14 million it raised in March last year, bringing the total in the round to £18.8 million.
The extension round was led by existing investors, Parkwalk Advisors and Hostplus via the IP Group Hostplus Innovation Fund, and includes participation from a new US-based investor, early-stage venture capital firm Modi Ventures.
A spinout from the University of Oxford, Brainomix has developed AI platforms that automate validated imaging biomarkers to improve both diagnosis and treatment decisions. The additional capital will enable Brainomix to expand further in the US market as the company advances deployment of its AI imaging platforms, Brainomix 360 Stroke and e-Lung, across multiple hospitals.
“This investment reflects strong confidence in our technology, our team, and the impact Brainomix 360 Stroke and e-Lung can have on patient care,” said chief executive and co-founder Michalis Papadakis.
“Stroke care depends on speed, while lung fibrosis care requires early identification and consistent clinical decision-making over time, underscoring the need for hospital technologies that support clinicians at the point of care,” he added.
According to Crunchbase, to date, the firm has raised £44.5 million in nine rounds of funding.
